Updates on Emerging GLP-1 Receptor Agonists

This program will include a discussion of off-label treatment and investigational agents and devices not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Adherence to Treatment Regimens

Overcoming Barriers to Treatment Adherence

Choosing the Best-Suited GLP-1 RAs for the Patient

Investigational GLP-1 RAs

How Are the Emerging GLP-1 Receptor Agonists Different?

Once-Weekly GLP-1 RA Semaglutide

Oral GLP-1 RA Semaglutide

ITCA 650 Continuous Delivery of Exenatide

Emerging GLP-1 Receptor Agonists

SUSTAIN-1: Safety and Efficacy of Once-Weekly Semaglutide Monotherapy vs Placebo

SUSTAIN-2: Safety and Efficacy of Once-Weekly Semaglutide vs Sitagliptin as Add-On to MET, TZD, or Both

Glycemic Control Demonstrated in SUSTAIN 1 to 5 Clinical Trials

SUSTAIN-6 CV Outcomes of Semaglutide

Updates From ADA on Retinopathy Findings

Safety Data

Dose Relationship of Oral Semaglutide on Glycemic Control and Body Weight

Emerging GLP-1 Receptor Agonists

FREEDOM-1 Study Design and Inclusion Criteria

FREEDOM-1 Safety and Efficacy Results at Week 39

FREEDOM-1 Substudy High Baseline HbA1c

FREEDOM-1 AEs

FREEDOM-2: Safety and Efficacy of ITCA 650 vs Sitagliptin With Background Metformin

Concluding Remarks

Abbreviations

Abbreviations (cont)